Maravai LifeSciences (MRVI) Q2 FY26 earnings call

Maravai LifeSciences delivered a strong second quarter, marked by significant profitability improvements and a strengthened balance sheet. The company's strategic focus on innovation, commercial execution, and operational excellence drove robust growth in high-margin mRNA segments, particularly GMP consumables and discovery. While full-year revenue guidance was maintained due to the inherent lumpiness of large orders, management expressed confidence in the underlying business momentum and long-term growth trajectory as customer programs advance.